{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:51:37Z","timestamp":1781657497336,"version":"3.54.5"},"reference-count":53,"publisher":"Norwegian Medical Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2012,1,24]]},"DOI":"10.4045\/tidsskr.11.0723","type":"journal-article","created":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T07:08:19Z","timestamp":1327561699000},"page":"155-8","source":"Crossref","is-referenced-by-count":2,"title":["Psykose ved Parkinsons sykdom"],"prefix":"10.4045","volume":"132","author":[{"given":"Arvid","family":"Rongve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Auning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Ehrt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"\u00c5rsland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","unstructured":"Aarsland D, Pedersen KF, Ehrt U et al. Nevropsykiatriske og kognitive symptomer ved Parkinsons sykdom. Tidsskr Nor Legeforen 2008; 128: 2072-6."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Rabey JM, Prokhorov T, Miniovitz A et al. Effect of quetiapine in psychotic Parkinson\u2019s disease patients: a double-blind labeled study of 3 months\u2019 duration. Mov Disord 2007; 22: 313\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17034006&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/mds.21116","DOI":"10.1002\/mds.21116"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Merims D, Balas M, Peretz C et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson\u2019s disease psychosis. Clin Neuropharmacol 2006; 29: 331\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17095896&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/01.WNF.0000236769.31279.19","DOI":"10.1097\/01.WNF.0000236769.31279.19"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Kurlan R, Cummings J, Raman R et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68: 1356\u2009\u2013\u200963. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17452579&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1212\/01.wnl.0000260060.60870.89","DOI":"10.1212\/01.wnl.0000260060.60870.89"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Ondo WG, Tintner R, Voung KD et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease. Mov Disord 2005; 20: 958\u2009\u2013\u200963. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15800937&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/mds.20474","DOI":"10.1002\/mds.20474"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Shotbolt P, Samuel M, Fox C et al. A randomized controlled trial of quetiapine for psychosis in Parkinson\u2019s disease. Neuropsychiatr Dis Treat 2009; 5: 327\u2009\u2013\u200932. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19557142&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2147\/NDT.S5335","DOI":"10.2147\/NDT.S5335"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Fernandez HH, Okun MS, Rodriguez RL et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci 2009; 119: 2196\u2009\u2013\u2009205. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19916848&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3109\/00207450903222758","DOI":"10.3109\/00207450903222758"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Meltzer HY, Mills R, Revell S et al. Pimavanserin, a\u00a0serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u2019s disease psychosis. Neuropsychopharmacology 2010; 35: 881\u2009\u2013\u200992. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19907417&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/npp.2009.176","DOI":"10.1038\/npp.2009.176"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med 1999; 340: 757\u2009\u2013\u200963. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10072410&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJM199903113401003","DOI":"10.1056\/NEJM199903113401003"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Pollak P, Tison F, Rascol O et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75: 689\u2009\u2013\u200995. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15090561&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/jnnp.2003.029868","DOI":"10.1136\/jnnp.2003.029868"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Morgante L, Epifanio A, Spina E et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson\u2019s disease. Neurol Sci 2002; 23 (suppl 2): S89\u2009\u2013\u200990. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12548358&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s100720200084","DOI":"10.1007\/s100720200084"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Breier A, Sutton VK, Feldman PD et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease. Biol Psychiatry 2002; 52: 438\u2009\u2013\u200945. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12242060&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0006-3223(02)01392-6","DOI":"10.1016\/S0006-3223(02)01392-6"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Ondo WG, Levy JK, Vuong KD et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17: 1031\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12360554&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/mds.10217","DOI":"10.1002\/mds.10217"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Goetz CG, Blasucci LM, Leurgans S et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55: 789\u2009\u2013\u200994. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10993997&dopt=Abstract","DOI":"10.1212\/WNL.55.6.789"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Aarsland D, Br\u00f8nnick K, Alves G et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2009; 80: 928\u2009\u2013\u200930. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19608786&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/jnnp.2008.166959","DOI":"10.1136\/jnnp.2008.166959"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"F\u00e9nelon G, Alves G. Epidemiology of psychosis in Parkinson\u2019s disease. J Neurol Sci 2010; 289: 12\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19740486&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.jns.2009.08.014","DOI":"10.1016\/j.jns.2009.08.014"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2001; 70: 734\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11385005&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/jnnp.70.6.734","DOI":"10.1136\/jnnp.70.6.734"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Aarsland D, Larsen JP, Cummins JL et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56: 595\u2009\u2013\u2009601. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10328255&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/archneur.56.5.595","DOI":"10.1001\/archneur.56.5.595"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Aarsland D, Br\u00f8nnick K, Ehrt U et al. Neuropsychiatric symptoms in patients with Parkinson\u2019s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36\u2009\u2013\u200942. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16820421&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/jnnp.2005.083113","DOI":"10.1136\/jnnp.2005.083113"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T et al. A\u00a012-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67: 996\u2009\u2013\u20091001. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20697051&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/archneurol.2010.166","DOI":"10.1001\/archneurol.2010.166"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Aarsland D, Andersen K, Larsen JP et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61: 1906\u2009\u2013\u200911. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15596611&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/archneur.61.12.1906","DOI":"10.1001\/archneur.61.12.1906"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Aarsland D, Larsen JP, Karlsen K et al. Mental symptoms in Parkinson\u2019s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866\u2009\u2013\u200974. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10521886&dopt=Abstract","DOI":"10.1002\/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Uc EY, Struck LK, Rodnitzky RL et al. Predictors of weight loss in Parkinson\u2019s disease. Mov Disord 2006; 21: 930\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16534756&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/mds.20837","DOI":"10.1002\/mds.20837"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Aarsland D, Larsen JP, Tandberg E et al. Predictors of nursing home placement in Parkinson\u2019s disease: a population-based, prospective study. J\u00a0Am Geriatr Soc 2000; 48: 938\u2009\u2013\u200942. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10968298&dopt=Abstract","DOI":"10.1111\/j.1532-5415.2000.tb06891.x"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson\u2019s disease. Neurology 1995; 45: 669\u2009\u2013\u200971. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7723953&dopt=Abstract","DOI":"10.1212\/WNL.45.4.669"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Ravina B, Marder K, Fernandez HH et al. Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22: 1061\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17266092&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/mds.21382","DOI":"10.1002\/mds.21382"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48 (suppl 6): S10\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9153155&dopt=Abstract","DOI":"10.1212\/WNL.48.5_Suppl_6.10S"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Baker WL, Silver D, White CM et al. Dopamine agonists in the treatment of early Parkinson\u2019s disease: a meta-analysis. Parkinsonism Relat Disord 2009; 15: 287\u2009\u2013\u200994. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18774743&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.parkreldis.2008.07.004","DOI":"10.1016\/j.parkreldis.2008.07.004"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Halliday G, Hely M, Reid W et al. The progression of pathology in longitudinally followed patients with Parkinson\u2019s disease. Acta Neuropathol 2008; 115: 409\u2009\u2013\u200915. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18231798&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00401-008-0344-8","DOI":"10.1007\/s00401-008-0344-8"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Kataoka H, Furiya Y, Morikawa M et al. Increased temporal blood flow associated with visual hallucinations in Parkinson''s disease with dementia. Movement disorders : official journal of the Movement Disorder Society 2008; 23: 464\u2009\u2013\u20095.","DOI":"10.1002\/mds.21923"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Boecker H, Ceballos-Baumann AO, Volk D et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007; 64: 984\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17620488&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/archneur.64.7.984","DOI":"10.1001\/archneur.64.7.984"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Rascol O, Payoux P, Ory F et al. Limitations of current Parkinson''s disease therapy. Ann Neurol 2003; 53 Suppl 3: S3\u2009\u2013\u200912; discussion S-5.","DOI":"10.1002\/ana.10513"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Meppelink AM, de Jong BM, Renken R et al. Impaired visual processing preceding image recognition in Parkinson\u2019s disease patients with visual hallucinations. Brain 2009; 132: 2980\u2009\u2013\u200993. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19755518&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093\/brain\/awp223","DOI":"10.1093\/brain\/awp223"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Nomura T, Inoue Y, Mitani H et al. Visual hallucinations as REM sleep behavior disorders in patients with Parkinson''s disease. Movement disorders : official journal of the Movement Disorder Society 2003; 18: 812\u2009\u2013\u20097.","DOI":"10.1002\/mds.10439"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Manni R, Pacchetti C, Terzaghi M et al. Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study. Neurology 2002; 59: 1979\u2009\u2013\u200981. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12499497&dopt=Abstract","DOI":"10.1212\/01.WNL.0000038351.32678.4A"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Meppelink AM, Koerts J, Borg M et al. Visual object recognition and attention in Parkinson''s disease patients with visual hallucinations. Movement disorders : official journal of the Movement Disorder Society 2008; 23: 1906\u2009\u2013\u200912.","DOI":"10.1002\/mds.22270"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995; 28: 240\u2009\u2013\u200958. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8546852&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1006\/brcg.1995.1255","DOI":"10.1006\/brcg.1995.1255"},{"key":"ref=38","unstructured":"Nasjonalt kompetansesenter for bevegelsesforstyrrelser. Veiledende retningslinjer for diagnostisering og behandling ved Parkinsons sykdom. Stavanger: Stavanger universitetssjukehus, 2010. http:\/\/www.sus.no\/omoss\/avdelinger\/nasjonalt-kompetansesenter-for-bevegelsesforstyrrelser\/Documents\/Retningslinjer%202010%20Parkinsons%20sykdom%20web.pdf%2012%2004%2010.pdf (9.12.2011)"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Miyasaki JM, Shannon K, Voon V et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996\u2009\u2013\u20091002. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16606910&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1212\/01.wnl.0000215428.46057.3d","DOI":"10.1212\/01.wnl.0000215428.46057.3d"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson\u2019s disease. Mov Disord 2003; 18: 831\u2009\u2013\u20092. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12815665&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/mds.10450","DOI":"10.1002\/mds.10450"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Wolters EC, Berendse HW. Management of psychosis in Parkinson\u2019s disease. Curr Opin Neurol 2001; 14: 499\u2009\u2013\u2009504. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11470967&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/00019052-200108000-00011","DOI":"10.1097\/00019052-200108000-00011"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson''s disease: Positive impact on long-term worsening. Movement disorders : official journal of the Movement Disorder Society 2008; 23: 1541\u2009\u2013\u20095.","DOI":"10.1002\/mds.22132"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989; 99 (suppl 1): 18\u2009\u2013\u200927. Crossref: http:\/\/dx.doi.org\/10.1007\/BF00442554","DOI":"10.1007\/BF00442554"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson\u2019s disease. Mov Disord 1990; 5: 225\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2388638&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/mds.870050307","DOI":"10.1002\/mds.870050307"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Thomas AA, Friedman JH. Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol 2010; 33: 14\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20023573&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/WNF.0b013e3181c47168","DOI":"10.1097\/WNF.0b013e3181c47168"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med 2004; 351: 2509\u2009\u2013\u200918. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15590953&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa041470","DOI":"10.1056\/NEJMoa041470"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease. Mov Disord 2006; 21: 1899\u2009\u2013\u2009907. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16960863&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/mds.21077","DOI":"10.1002\/mds.21077"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Ballard C, Hanney ML, Theodoulou M et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8: 151\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19138567&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S1474-4422(08)70295-3","DOI":"10.1016\/S1474-4422(08)70295-3"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934\u2009\u2013\u200943. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16234500&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/jama.294.15.1934","DOI":"10.1001\/jama.294.15.1934"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Herrmann N, Li A, Lanct\u00f4t K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother 2011; 12: 787\u2009\u2013\u2009800. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21385152&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1517\/14656566.2011.558006","DOI":"10.1517\/14656566.2011.558006"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19520613&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S1474-4422(09)70146-2","DOI":"10.1016\/S1474-4422(09)70146-2"},{"key":"ref=52","doi-asserted-by":"crossref","unstructured":"Litvinenko IV, Odinak MM, Mogil\u2019naya VI et al. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson\u2019s disease complicated by dementia. Neurosci Behav Physiol 2010; 40: 149\u2009\u2013\u200955. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20033305&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s11055-009-9244-1","DOI":"10.1007\/s11055-009-9244-1"},{"key":"ref=53","doi-asserted-by":"crossref","unstructured":"Emre M, Tsolaki M, Bonuccelli U et al. Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969\u2009\u2013\u200977. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20729148&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S1474-4422(10)70194-0","DOI":"10.1016\/S1474-4422(10)70194-0"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:55:19Z","timestamp":1781654119000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2012\/01\/oversiktsartikkel\/psykose-ved-parkinsons-sykdom"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,24]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1,24]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.11.0723","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,24]]}}}